Vaccine effectiveness against Omicron variants may change over time

By Elissa Wolfson, The Science Advisory Board assistant editor

February 6, 2023 -- Researchers from The Chinese University of Hong Kong and the Harvard T.H. Chan School of Public Health in Boston, Massachusetts collaborated on a case-control study and found that two vaccines were generally effective over time against severe outcomes from SARS-CoV-2 Omicron infection. The research, published February 3 in the journal JAMA Network Open, also showed that protection among older individuals was more likely to wane six months after the second dose.

As few studies have evaluated the waning of vaccine effectiveness against severe SARS-CoV-2 Omicron infection outcomes, the researchers sought to examine changes in vaccine effectiveness against hospitalization and mortality due to the Omicron variant over time. They focused on Hong Kong, which provides inactivated and mRNA vaccines, but had a population with limited protection from natural infections before the Omicron variant emerged.

This case-control study included adults with SARS-CoV-2 Omicron variant infection who died or were hospitalized in Hong Kong from January 1 to June 5, 2022 (case participants), and adults with SARS-CoV-2 Omicron sampled from the public health registry during the study period (control participants), who were matched to case participants by propensity score.

The estimated vaccine effectiveness against death, death or hospitalization, and death among hospitalized patients was calculated as an odds ratio of 1.0, indicating that the odds of vaccine effectiveness among case participants were similar to the odds of vaccine effectiveness among controls. The adjusted odds ratio was obtained by conditional logistic regression adjusted with covariates for each period following vaccination.

There were 32,823 case participants. Of these, 25,546 or 77.8% were 65 years of age or older; 16,930 or 47.4% were female. Of the 131,328 control participants, 100,041 or 76.2% were 65 years of age or older; 66,625 or 46.6% were female in the sample analyzed for the death or hospitalization outcome.

Vaccine effectiveness against death or hospitalization was maintained for at least six months after the second dose of both CoronaVac and BNT162b2 vaccines. Vaccine effectiveness against death in those aged 18 to 49 years was found to be 86.4% and 92.9% for those receiving two doses of CoronaVac and BNT162b2, respectively, while effectiveness dropped for patients aged 80 years or older to 61.4% and 52.7% for CoronaVac and BNT162b2, respectively. Nevertheless, overall vaccine effectiveness against death four to six months after the third dose was greater than 90% for CoronaVac, BNT162b2, and a mixed vaccine schedule.

The researchers concluded that while vaccines were generally estimated to be effective against severe outcomes caused by SARS-CoV-2 Omicron infection, protection in older patients was more likely to wane six months after the second dose. Therefore, they recommend older patients have booster doses to restore immunity, particularly in areas like Hong Kong, where third-dose coverage is insufficient among older residents.

mRNA COVID-19 booster rates low among immunocompromised
Researchers have found low adherence to the Centers for Disease Control and Prevention's mRNA monovalent COVID-19 booster recommendations among immunocompromised...
Omicron subvariants dodge neutralizing antibodies: study
Three subvariants of SARS-CoV-2 currently sweeping through the U.S. are better at evading vaccine- and infection-generating neutralizing antibodies than...
New antibody neutralizes all known SARS-CoV-2 variants: study
An antibody developed at Boston Children’s Hospital neutralizes all known SARS-CoV-2 variants, including omicron subvariants, which may inform the design...
Pfizer-BioNTech study supports 97% effectiveness of COVID-19 vaccine
Real-world evidence released by the Israel Ministry of Health demonstrates dramatically lower incidence rates of COVID-19 disease in individuals fully...
Pfizer, BioNTech study 3rd booster of vaccine to protect against variants
Pfizer and BioNTech have started to evaluate the safety and immunogenicity of a third dose of their COVID-19 vaccine BNT162b2 as a booster on immunity...
Older adults likely to get COVID-19 vaccine, but some say they want to wait
A new poll of older adults indicates that that there is some hesitancy among the group when asked if they would get an effective COVID-19 vaccine.
Will mutation of the SARS-CoV-2 virus affect vaccine effectiveness?
What impact will mutation of the SARS-CoV-2 virus have on the effectiveness of COVID-19 vaccines that are in development? In a new study published in...
Sinovac receives $15M for COVID-19 vaccine
Biopharmaceutical company Sinovac Biotech announced that Advantech Capital and Vivo Capital invested $15 million in the firm's research and development...

Copyright © 2023 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter